AMA proposes who's liable when clinical AI harms patients

The American Medical Association published a liability framework on Oct. 29 proposing how fault should be assigned when clinical AI tools cause patient harm. Becker's Hospital Review reported that the AMA built the framework around aligning responsibility with each party's authority and actual ability to prevent or catch the harm, rather than defaulting liability to whichever party is easiest to sue. A parallel brief covered by HealthSystemCIO frames it as a duty-of-care standard: health systems that deploy clinical AI are now expected to own selection, validation and ongoing monitoring of the tools they put in front of clinicians — not just the vendor contract that licenses them.

That distinction matters for anyone building the software layer, not just the model. A generative AI integration partner is effectively building the part of the system the AMA just said carries real legal exposure: the validation checks, audit trails and monitoring hooks that let a deployer actually demonstrate it was watching the tool, not just running it.

The AMA's rationale is that existing liability law was written for tools a single party fully controls — a device, a drug, a decision a physician makes alone. Clinical AI breaks that model because developers, deploying health systems and treating physicians each control a different slice of the risk, and current frameworks leave physicians exposed for failures they have no practical way to detect.

How the AMA splits the four parties

The framework assigns liability along four lines. Developers must demonstrate and maintain the safety and effectiveness of what they ship, including after deployment — a tool that degrades silently as real-world data drifts from training data isn't the deployer's problem to catch first. Deployers — the health systems and clinics that select, implement and govern a tool — are accountable for how it's monitored once it's live, including whether anyone is actually reviewing its outputs over time. Physicians retain responsibility for the clinical judgment they can meaningfully exercise, but the framework explicitly protects them from liability for errors they can't reasonably detect, citing the example of a triage model that silently deprioritizes a patient while the physician only ever sees an already-reordered list. Patients keep a path to a remedy when a defective tool or an actionable institutional failure causes harm.

What this changes for teams building clinical AI features

Until now, a lot of GenAI features shipped into clinical workflows with a demo-quality evaluation step and a vague promise to "monitor it later." The AMA framework gives hospital legal and compliance teams a concrete reason to push back on that: if a deployer is now expected to show ongoing validation, that requirement has to be designed into the product from day one — logging what the model saw, what it output, how confident it was, and whether a human reviewed it — not bolted on after a regulator or plaintiff's attorney asks for it. Healthcare IT News notes the AMA frames this as a risk-based approach, meaning the bar for monitoring and documentation scales with how much clinical consequence a given AI feature carries — a sepsis-risk alert needs a different audit trail than an appointment-reminder chatbot.

Clinicians, for their part, gain an explicit right to decline an unproven AI recommendation without that refusal counting against them — which means products that quietly assume clinicians will defer to the model's output need a harder look at how dissent and override get logged too.